Switch theme
Sign up to access all valuation multiples
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
2019
130
LTM Revenue $9.6M
LTM EBITDA -$175M
$348M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zenas BioPharma has a last 12-month revenue (LTM) of $9.6M and a last 12-month EBITDA of -$175M.
In the most recent fiscal year, Zenas BioPharma achieved revenue of $5.0M and an EBITDA of -$164M.
Zenas BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zenas BioPharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $9.6M | XXX | $5.0M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$175M | XXX | -$164M | XXX | XXX | XXX |
| EBITDA Margin | -1817% | XXX | -3275% | XXX | XXX | XXX |
| EBIT | -$177M | XXX | -$164M | XXX | XXX | XXX |
| EBIT Margin | -1833% | XXX | -3278% | XXX | XXX | XXX |
| Net Profit | -$171M | XXX | -$157M | XXX | XXX | XXX |
| Net Margin | -1773% | XXX | -3140% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Zenas BioPharma's stock price is $16.
Zenas BioPharma has current market cap of $659M, and EV of $348M.
See Zenas BioPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $348M | $659M | XXX | XXX | XXX | XXX | $-7.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Zenas BioPharma has market cap of $659M and EV of $348M.
Zenas BioPharma's trades at 69.5x EV/Revenue multiple, and -2.1x EV/EBITDA.
Equity research analysts estimate Zenas BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zenas BioPharma has a P/E ratio of -3.9x.
See valuation multiples for Zenas BioPharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $659M | XXX | $659M | XXX | XXX | XXX |
| EV (current) | $348M | XXX | $348M | XXX | XXX | XXX |
| EV/Revenue | 36.0x | XXX | 69.5x | XXX | XXX | XXX |
| EV/EBITDA | -2.0x | XXX | -2.1x | XXX | XXX | XXX |
| EV/EBIT | -2.0x | XXX | -2.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.9x | XXX | -4.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialZenas BioPharma's last 12 month revenue growth is 85%
Zenas BioPharma's revenue per employee in the last FY averaged $38K, while opex per employee averaged $1.3M for the same period.
Zenas BioPharma's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zenas BioPharma's rule of X is -1606% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Zenas BioPharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 85% | XXX | 106% | XXX | XXX | XXX |
| EBITDA Margin | -1817% | XXX | -3275% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | -3190% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1606% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $38K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2783% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3378% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zenas BioPharma acquired XXX companies to date.
Last acquisition by Zenas BioPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Zenas BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Zenas BioPharma founded? | Zenas BioPharma was founded in 2019. |
| Where is Zenas BioPharma headquartered? | Zenas BioPharma is headquartered in United States of America. |
| How many employees does Zenas BioPharma have? | As of today, Zenas BioPharma has 130 employees. |
| Who is the CEO of Zenas BioPharma? | Zenas BioPharma's CEO is Mr. Leon Oliver Moulder, Jr. |
| Is Zenas BioPharma publicy listed? | Yes, Zenas BioPharma is a public company listed on NAS. |
| What is the stock symbol of Zenas BioPharma? | Zenas BioPharma trades under ZBIO ticker. |
| When did Zenas BioPharma go public? | Zenas BioPharma went public in 2024. |
| Who are competitors of Zenas BioPharma? | Similar companies to Zenas BioPharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Zenas BioPharma? | Zenas BioPharma's current market cap is $659M |
| What is the current revenue of Zenas BioPharma? | Zenas BioPharma's last 12 months revenue is $9.6M. |
| What is the current revenue growth of Zenas BioPharma? | Zenas BioPharma revenue growth (NTM/LTM) is 85%. |
| What is the current EV/Revenue multiple of Zenas BioPharma? | Current revenue multiple of Zenas BioPharma is 36.0x. |
| Is Zenas BioPharma profitable? | Yes, Zenas BioPharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zenas BioPharma? | Zenas BioPharma's last 12 months EBITDA is -$175M. |
| What is Zenas BioPharma's EBITDA margin? | Zenas BioPharma's last 12 months EBITDA margin is -1817%. |
| What is the current EV/EBITDA multiple of Zenas BioPharma? | Current EBITDA multiple of Zenas BioPharma is -2.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
